68Ga-TP1580 as a novel molecular probe for HER2-positive tumor imaging using MicroPET

被引:0
|
作者
Zhong, Jinxiu [1 ]
Pan, Donghui [2 ]
Guan, Yan-xing [3 ]
机构
[1] Nanchang Univ, Jiangxi Canc Hosp, Nanchang 330006, Jiangxi, Peoples R China
[2] Jiangsu Inst Nucl Med, Key Lab Nucl Med, Wuxi 210463, Jiangsu, Peoples R China
[3] Nanchang Univ, Affiliated Hosp 1, Dept Nucl Med Radiol, Nanchang 330006, Jiangxi, Peoples R China
关键词
HER2; MicroPET; Imaging; Peptides; BREAST-CANCER; CLINICAL-APPLICATIONS; HER2; EXPRESSION; PET; RECEPTOR; ANTAGONISTS; PEPTIDES; TOMOGRAPHY; CARCINOMAS; THERAPY;
D O I
10.1007/s10967-022-08236-x
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
HER2 is an attractive target for the treatment of breast cancer. Tc-99(m)-labeled HER2-specific binding to the small molecule mimetic peptide B2-S22-AFA shows the potential of detecting HER2 expression in vivo (Zhang in Transl Oncol 10:518-526, 2017). However, the low resolution of SPECT-CT imaging and the inability to quantitatively analyze may partially limit its wide use.Ga-68 is an excellent PET radionuclide due to availability, nearly quantitative reaction, and short physical half-life. In this study, Ga-68-labeled-NOTA- B2-S22-AFA (hereinafter referred to as Ga-68-TP1580) was applied for PET-CT imaging in HER2 breast cancer xenografts mice. In vitro studies and MicroPET imaging were performed in the SKBR-3 breast cancer model. Ga-68-TP1580 could be produced within 20 min with 93.2 +/- 2.1% yield and the radiochemical purity was greater than 95%. The tracer was stable in PBS and human serum for at least 2 h. MicroPET imaging revealed that the SKBR-3 xenografts were visualized and the tumor uptakes were 1.22 +/- 0.04, 0.71 +/- 0.07, and 0.43 +/- 0.04% ID/g at 0.5 h, 1 h, and 2 h.The corresponding tumor-to-blood and tumor-to-muscle ratios were 1.05 +/- 0.06, 1.34 +/- 0.21, and 1.33 +/- 0.57, respectively, and 4.02 +/- 1.39, 7.47 +/- 2.86, and 5.82 +/- 1.98 at 0.5 h, 1 h, and 2 h. No significant decrease in tumor uptake of Ga-68-TP1580 was seen after injection of excess unlabeled TP1580.In conclusion, TP1580 can be labeled by Ga-68 with high radiochemical purity (> 95%), good vitro stability (keep consistent radiochemical purity > 95% for more than 2 h).Ga-68-TP1580 can combine with target tissue and show some tumor uptake in SKBR-3 xenografts, but not be blocked by NOTA-B2-S22-AFA which indicates poor specificity.
引用
收藏
页码:1531 / 1543
页数:13
相关论文
共 50 条
  • [21] A direct comparison of tumor angiogenesis with 68Ga-labeled NGR and RGD peptides in HT-1080 tumor xenografts using microPET imaging
    Shao, Yahui
    Liang, Wansheng
    Kang, Fei
    Yang, Weidong
    Ma, Xiaowei
    Li, Guiyu
    Zong, Shu
    Chen, Kai
    Wang, Jing
    AMINO ACIDS, 2014, 46 (10) : 2355 - 2364
  • [22] A preliminary study of a 68Ga-labeled PET probe for HER2 imaging
    Chen, Kaiwen
    Wang, Xiangwei
    Xu, Xiaoping
    Wang, Xiao
    He, Simin
    Zhang, Jianping
    Sun, Yuyun
    Yang, Shiping
    Song, Shaoli
    NEW JOURNAL OF CHEMISTRY, 2023, 47 (28) : 13378 - 13386
  • [23] ICG-Dimeric Her2-Specific Affibody Conjugates for Tumor Imaging and Photothermal Therapy for Her2-Positive Tumors
    Jia, Dianlong
    Liu, Huimin
    Zheng, Shuhui
    Yuan, Dandan
    Sun, Ruohan
    Wang, Fei
    Li, Yang
    Li, Hui
    Yuan, Fengjiao
    Fan, Qing
    Zhao, Zhenxiong
    MOLECULAR PHARMACEUTICS, 2023, 20 (01) : 427 - 437
  • [24] Peptides Targeting HER2-Positive Breast Cancer Cells and Applications in Tumor Imaging and Delivery of Chemotherapeutics
    Cavallaro, Palmira Alessia
    De Santo, Marzia
    Belsito, Emilia Lucia
    Longobucco, Camilla
    Curcio, Manuela
    Morelli, Catia
    Pasqua, Luigi
    Leggio, Antonella
    NANOMATERIALS, 2023, 13 (17)
  • [25] PET Imaging of Cardiac Wound Healing Using a Novel [68Ga]-Labeled NGR Probe in Rat Myocardial Infarction
    Tillmanns, Jochen
    Schneider, Magdalena
    Fraccarollo, Daniela
    Schmitto, Jan-Dieter
    Laenger, Florian
    Richter, Dominik
    Bauersachs, Johann
    Samnick, Samuel
    MOLECULAR IMAGING AND BIOLOGY, 2015, 17 (01) : 76 - 86
  • [26] Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer
    Wei Chen
    Xiaofeng Li
    Lei Zhu
    Jianjing Liu
    Wengui Xu
    Ping Wang
    Cancer Biology & Medicine , 2017, (03) : 271 - 280
  • [27] Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay
    Desai, Neelam V.
    Torous, Vanda
    Parker, Joel
    Auman, James T.
    Rosson, Gary B.
    Cruz, Cassandra
    Perou, Charles M.
    Schnitt, Stuart J.
    Tung, Nadine
    BREAST CANCER RESEARCH, 2018, 20
  • [28] Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer
    Chen, Wei
    Li, Xiaofeng
    Zhu, Lei
    Liu, Jianjing
    Xu, Wengui
    Wang, Ping
    CANCER BIOLOGY & MEDICINE, 2017, 14 (03) : 271 - 280
  • [29] In Vivo Imaging of Folate Receptor Positive Tumor Xenografts Using Novel 68Ga-NODAGA-Folate Conjugates
    Fani, Melpomeni
    Tamma, Maria-Luisa
    Nicolas, Guillaume P.
    Lasri, Elisabeth
    Medina, Christelle
    Raynal, Isabelle
    Port, Marc
    Weber, Wolfgang A.
    Maecke, Helmut R.
    MOLECULAR PHARMACEUTICS, 2012, 9 (05) : 1136 - 1145
  • [30] In vivo preclinical assessment of novel 68Ga-labelled peptides for imaging of tumor associated angiogenesis using positron emission tomography imaging
    Denes, Noemi
    Kis, Adrienn
    Szabo, Judit P.
    Joszai, Istvan
    Hajdu, Istvan
    Arato, Viktoria
    Enyedi, Kata Nora
    Mezo, Gabor
    Hunyadi, Janos
    Trencsenyi, Gyorgy
    Kertesz, Istvan
    APPLIED RADIATION AND ISOTOPES, 2021, 174